Media Center

In the media

Ability logra financiación de la FDA y abre una ronda en Capital Cell

Expansión

22/10/2020

Ability Pharma capta dos millones de dólares de la FDA para su ensayo clínico de páncreas

Planta Doce

22/10/2020

AbilityPharma capta 5 M€ per a un assaig contra el càncer de pàncreas

ARA

25/03/2020

Ability Pharma receives the acknowledgement from Cerdanyola Empresarial

Parc UAB newsletter

22/11/2019

Ability reinforces the direction and rises 2 million euros from Inveready and Everis

Expansión

13/09/2019

Ability Pharma rises 3.5M€ to finish the clinical trial in cancer

Ara

13/09/2019

A Catalan drug can extend the life expectancy of patients with lung and endometrial cancer

RAC1

06/06/2019

Nine Catalan biotechs among the most promising in Europe

La Vanguardia

28/05/2019

AbilityPharma will start research for cancer in China

El Punt Avui

05/02/2019

The partner of AbilityPharma in China starts clinical trials with the licensed drug

Expansión

04/02/2019

AbilityPharma rises 1.2M euros with the biggest round of Capitall Cell

Ara

10/12/2018

AbilityPharma recibe su tercera designación de medicamento huérfano por la FDA

Expansión

08/11/2018

TechShare, el programa que abre las puertas de la Bolsa a las pymes biotech

Innovaspain

26/09/2018

Cómo facilitar la salida a bolsa de empresas biotecnológicas

Diario Medico

26/09/2018

ABILITY PHARMA COMENÇA LA FASE 2 DEL SEU NOU ANTICANCERIGEN

La Vanguardia

20/09/2018

ABILITYPHARMA ABRE UNA RONDA PARA LUCHAR CONTRA EL CÁNCER

Expansión

13/09/2018

The FDA approves a clinical trial of AbilityPharma

Expansión

20/02/2018

Ability Pharma gets FDA nod for a new clinical trials

Diari de Sabadell

20/02/2018

Ability receives FDA authorization to start clinical trials

Expansión

14/12/2017

Ability Pharma seeks 2.5 million to expand clinical trials

Expansión

09/10/2017

LATEST NEWS

05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

Press Release

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

Press Release

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

Press Release

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG